Japan Approves Novocure's Optune Pax for Pancreatic Cancer
NVCR sits 64% above its 52-week low of $9.82.
Summary
Japan's MHLW approved Optune Pax for unresectable locally advanced pancreatic cancer, expanding the device's commercial reach into a major oncology market. The approval follows positive Phase 3 PANOVA-3 data showing statistically significant overall survival improvement. This is the third major regulatory nod for Optune Pax after FDA approval in February 2026 and CE Mark in June 2026. Japan has approximately 46,000 pancreatic cancer diagnoses annually, representing a meaningful commercial opportunity. The approval validates the therapy's clinical profile and supports further global expansion.
At the time of this announcement, NVCR was trading at $16.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $9.82 to $21.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.